+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021

  • PDF Icon

    Drug Pipelines

  • March 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5331197
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Islet Amyloid Polypeptide - Drugs in Development, 2021, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle.

The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 10 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Gastrointestinal and Musculoskeletal Disorders which include indications Type 2 Diabetes, Obesity, Type 1 Diabetes (Juvenile Diabetes), Alzheimer's Disease, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Neurodegenerative Diseases, Non Alcoholic Fatty Liver Disease (NAFLD), Osteoarthritis, Pancreatic Diseases and Parkinson's Disease.

Furthermore, this report also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
  • The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics

Reasons to Buy


  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Introduction
  • Report Coverage

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development
  • ADM Therapeutics
  • Adocia SAS
  • Eli Lilly and Co
  • Gubra ApS
  • Neurimmune Holding AG
  • Nordic Bioscience AS
  • reMYND NV
  • Wren Therapeutics Ltd
  • Zealand Pharma AS

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles
(insulin aspart + pramlintide) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

(insulin lispro + pramlintide) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

AC-253 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ADM-116 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

DACRA-089 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

GUI-17 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

GUI-35 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

KBP-056 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

KBP-088 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

NI-203 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ReS-39 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecules to Inhibit IAPP for Neurodegenerative Diseases and Pancreatic Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Synthetic Peptide for Obesity and Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Synthetic Peptides to Inhibit ABPP and IAPP for Alzheimer's Disease and Type 2 Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ZP-4982 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

ZP-5461 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products
  • Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones
  • Featured News & Press Releases
  • Jun 14, 2019: ADA2019: Find the two Adocia abstracts including the “BioChaperone Glucagon Exenatide” Poster online
  • Jun 04, 2019: Adocia presents on BioChaperone Pramlintide Insulin at the American Diabetes Association® 79th Scientific Sessions
  • Feb 12, 2019: Adocia to present new clinical data on Pramlintide-Prandial Insulin combinations at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
  • Sep 05, 2018: Adocia announces positive topline results for the first clinical study of BioChaperone Pramlintide Insulin in people with type 1 diabetes
  • Apr 16, 2018: Adocia initiates First-in-Human Clinical Study of BioChaperone Pramlintide Insulin in people with type 1 diabetes
  • Apr 03, 2018: Taming an unruly target in diabetes
  • May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
  • Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes
  • Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions
  • May 05, 2014: reMYND’s novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models
  • Apr 10, 2013: Centennial Lecture features research on restoring memory and movement
  • Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by ADM Therapeutics, 2021
  • Pipeline by Adocia SAS, 2021
  • Pipeline by Eli Lilly and Co, 2021
  • Pipeline by Gubra ApS, 2021
  • Pipeline by Neurimmune Holding AG, 2021
  • Pipeline by Nordic Bioscience AS, 2021
  • Pipeline by reMYND NV, 2021
  • Pipeline by Wren Therapeutics Ltd, 2021
  • Pipeline by Zealand Pharma AS, 2021
  • Dormant Projects, 2021
  • Discontinued Products, 2021

List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ADM Therapeutics
  • Adocia SAS
  • Eli Lilly and Co
  • Gubra ApS
  • Neurimmune Holding AG
  • Nordic Bioscience AS
  • reMYND NV
  • Wren Therapeutics Ltd
  • Zealand Pharma AS